Medical School

Hacettepe University Medical Faculty

Post-Graduate Training

Hacettepe University Medical Faculty

Professional Experience

Hacettepe University Medical Faculty Internal Medicine 2006-2011
Hacettepe Medical Faculty Oncology 2011-2015
SBÜ Konya Education & Research Hospital  2015-2016
Medicana International Ankara Hospital 2016-2018
İstinye University Medical Faculty - Medical Park Trabzon Hospital (2018-2020)

Medical Interests

Breast cancerColon cancerLung cancerLymphoma
Special Procedures

Scientific Publications

1)Sarici F, Sunar V, Aksoy S. The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer. International Journal of Hematology and Oncology 2020; 30(1):1-10.

2)Sarici F, Babacan T, Büyükhatipoglu H et al. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. J BUON.2016;21(4):826-31.

3) Sarici F, Kertmen N, Aslan A, Taşdemir V, Babacan T, Kilickap S, Ozdemir E, Barista İ, Türker A, Kars A.     Anthracyclin – Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. International Journal of Hematology and Oncology 2016; 26(2):089-095.

4)Ateş O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakaş Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundağ K.Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375-81.

5)Ateş O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, Sever AR, Altundağ K.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. Springerplus. 2016;19(5):486.

6)Sarici F, Babacan T, Altudağ K, Balakan O, GulluI. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON.2013;18(3):799.

7)Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundağ K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON.2015;20(3):737-45.

8)Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundağ K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON.2015;20(1):50-6.

9)Babacan T, Efe O, Hasirci AS, Demirci F, Büyükhatipoğlu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ateş O, Aksoy S, Sever AR, Altundağ K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori.2015;101(4):418-23.

10)Sarici F, Babacan T, Petekkaya I, Gezgen G, Roach EC, Altundağ K. Colon involvement in a chronic lymphocytic leukemia patient. J BUON. 2013;18(1):291-2.

11)Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akın S, Arik Z, Aslan A, Ateş O, Aksoy S, Ozisik Y, Altundağ K. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON. 2015;20(1):35-9.
Memberships:Associatio of Internal Medicine SpecialistsMedical Oncology AssociationAnkara Chamber of Medicine (Turkish Medical Association)

Medical Second Opinion
✓ Valid

I have read the Information in accordance with the General Data Protection Regulation. I accept that my personal data is processed within the specified scope and that I can be contacted for health services.

Medicana Hospital Business Inc. and Medicana Samsun Private Healthcare Services Inc.'s controlling and affiliated companies ("Medicana Health Group") can provide all kinds of information, questionnaires, publicity, opening, invitations. and activity etc. I agree to send Commercial Electronic Messages (call, sms, e-mail, etc.) to me within the scope of reminders and other communication activities.


Let Us Call You